Benefits of dolutegravir treatment for all substantially outweigh the risks
New BHIVA guidelines on HIV care in pregnancy and after birth
All people with HIV-2 should receive HIV treatment – without it, most will progress to AIDS and death
Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir
Drug resistance accumulates fast in people with low but detectable viral loads, Kenyan study finds
US doctors’ organisation endorses event-based PrEP for the first time
Why are some countries slow to implement HIV treatment guidelines?
Dolutegravir-based ART recommended for all – if reliable contraception is available
Brazil confirms dolutegravir is the most effective drug for first-line HIV treatment
